問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Principal Investigator

白禮源

List

138Cases

2018-10-24 - 2021-12-31

Phase I/II

Open-Label, Multicenter Study of D07001-Softgel Capsules (Oral Gemcitabine Hydrochloride) in Subjects With Unresectable, Metastatic or Locally Advanced Gastrointestinal (GI) Cancer in Dose-Escalation Phase and in Subjects With Advanced Biliary Tract Cancer (BTC) Following Primary Chemotherapy or Combined Chemoradiotherapy (CCRT) in Dose-Expansion Phase

  • Condition/Disease

    Advanced Biliary Tract Cancer (BTC)

  • Test Drug

    D07001-Softgel Capsules

Participate Sites
5Sites

Terminated4Sites

陳明晃
Taipei Veterans General Hospital

Division of Hematology & Oncology

白禮源
China Medical University Hospital-Taipei

未分科

2015-09-15 - 2019-02-28

Phase II

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of S-1 and Oxaliplatin With or Without Ramucirumab as First-line Therapy Followed by Paclitaxel With Ramucirumab as Second-line Therapy in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

  • Condition/Disease

    Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

  • Test Drug

    Ramucirumab

Participate Sites
6Sites

Terminated5Sites

陳仁熙
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

白禮源
China Medical University Hospital-Taipei

未分科

2020-12-01 - 2023-12-31

Phase III

A Phase 3, Open-Label, Randomized Study of Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients with Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements-FOENIX-CCA3

  • Condition/Disease

    Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

  • Test Drug

    Futibatinib（TAS-120）

Participate Sites
6Sites

Recruiting6Sites

2016-01-01 - 2021-05-31

Phase I/II

A Phase I/II Study of CX-4945 in Combination with Gemcitabine plus Cisplatin in the Frontline Treatment of Patients with Cholangiocarcinoma

  • Condition/Disease

    Cholangiocarcinoma

  • Test Drug

    CX-4945

Participate Sites
7Sites

Recruiting6Sites

白禮源
China Medical University Hospital-Taipei

未分科

陳明晃
Taipei Veterans General Hospital

Division of Hematology & Oncology

2017-06-01 - 2019-12-31

Phase II/III

A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Varlitinib Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Advanced or Metastatic Biliary Tract Cancer as Second Line Systemic Therapy

  • Condition/Disease

    Advanced or Metastatic Biliary Tract Cancer

  • Test Drug

    Varlitinib

Participate Sites
7Sites

Terminated5Sites

白禮源
China Medical University Hospital-Taipei

未分科

趙毅
Taipei Veterans General Hospital

Division of Hematology & Oncology

2013-07-01 - 2015-01-31

Phase II

Randomized, Open Label, Phase 2 Study of MM-111 and Paclitaxel with or without Trastuzumab in Patients with ‘Traditional’ and ‘Non-Traditional’ HER2 Expressing Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach Who Have Failed Front Line Metastatic or Locally Advanced Therapy

  • Condition/Disease

    Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach

  • Test Drug

    MM-111

Participate Sites
4Sites

Terminated3Sites

Study ended1Sites

白禮源
China Medical University Hospital

Division of Hematology & Oncology

2018-08-18 - 2022-07-11

Phase III

FIGHT: A Phase 3 Randomized, Double-Blind, Controlled Study Evaluating FPA144 and Modified FOLFOX6 in Patients with Previously Untreated Advanced Gastric and Gastroesophageal Cancer: Phase 3 Preceded by Dose-Finding in Phase 1

  • Condition/Disease

    Untreated Advanced Gastric and Gastroesophageal Cancer

  • Test Drug

    FPA144

Participate Sites
9Sites

Not yet recruiting3Sites

Recruiting1Sites

Terminated4Sites

白禮源
China Medical University Hospital-Taipei

未分科

2016-08-31 - 2018-12-31

Phase III

A Randomized, Open-label, Japan-Korea-Taiwan Collaborative Phase 3 Study to Compare the Efficacy of Nimotuzumab and Irinotecan Combination Therapy versus Irinotecan Monotherapy as Second Line Treatment in Subjects with Advanced or Recurrent Gastric and Gastroesophageal Junction Cancer

  • Condition/Disease

    Advanced or Recurrent Gastric and Gastroesophageal Junction Cancer

  • Test Drug

    DE-766 injection 50 mg/10mL vial

Participate Sites
11Sites

Terminated10Sites

趙毅
Taipei Veterans General Hospital

2020-09-20 - 2024-02-22

Phase I

A Phase I, Open-Label Study to Assess the Safety, Tolerability, and Preliminary Efficacy of OBI-866/OBI-821, a Novel Anti-Stage-Specific Embryonic Antigen-4 (SSEA-4) Active Immunotherapy, in Patients with Advanced/Metastatic Cancers of the Ovary, Kidney, Brain, Pancreas, Breast or Lung

  • Condition/Disease

    Cancers of the Ovary, Kidney, Brain, Pancreas, Breast or Lung

  • Test Drug

    OBI-866 (SSEA-4) / OBI-821 (adjuvant)

Participate Sites
2Sites

Recruiting2Sites

白禮源
China Medical University Hospital

Division of Hematology & Oncology

2020-08-01 - 2022-08-31

Phase I/II

A Phase I/II, Open Label, Dose Escalation and Cohort Expansion Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of OBI 888 in Patients with Locally Advanced or Metastatic Solid Tumors.

  • Condition/Disease

    Metastatic Solid Tumors / Locally Advanced Solid Tumors

  • Test Drug

    OBI 888

Participate Sites
3Sites

Not yet recruiting2Sites

Recruiting1Sites

1 10 11 12 13 14
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB